As per the agreement, Delcath will provide JW Goethe with logistics and clinical training support in the performance of chemosaturation therapy using the Chemosat system.
JW Goethe Institute for Diagnostic and Interventional Radiology director Thomas Vogl said clinical research suggests that chemosaturation therapy using the Chemosat system will provide them a clinically significant tool in treating liver metastases with melphalan.
"We’re eager to start providing therapy to our patients and explore the additional potential benefits of Delcath’s newest generation product," Vogl said.
